Cargando…
Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930418/ https://www.ncbi.nlm.nih.gov/pubmed/36628537 http://dx.doi.org/10.1002/acn3.51727 |
Ejemplares similares
-
Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies
por: Kister, Ilya, et al.
Publicado: (2022) -
Erratum: Omicron and other variants of SARS-CoV-2 roles of vaccines and herd immunity in protecting from the emerging strains
Publicado: (2022) -
Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients
por: Trümpelmann, Susan, et al.
Publicado: (2022) -
Erratum: A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variants
Publicado: (2022) -
Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies
por: Tortorella, Carla, et al.
Publicado: (2022)